Legionella is a facultative intracellular gram-negative coccobacillus with the reservoir being a common water body or aerosolized system. Although human-to-human transmission is uncommon it still presents as a public health hazard both due to the associated mortality and widespread transmission through a common source [1,2]. Legionella classically causes atypical pneumonia (Legionnaires' disease). The common signs and symptoms include but are not limited to fever, chills, headache, hyponatremia, diarrhea, relative bradycardia, and altered mental status. A third of patients also present with blood-streaked phlegm or hemoptysis. It is also known to cause a milder Pontiac fever (flu-like symptoms without pneumonia) in immunocompetent patients. Despite these distinct features, it may often be misdiagnosed, and if left untreated, has a mortality of 30–50% [1]. The incubation period for Legionnaires’ disease is usually 2–10 days, however, up to 16 days have been reported [3].

The incidence of Legionnaires disease varies greatly with the level of surveillance and reporting. The USA, Europe, and Australia report 10–15 cases per million population each year with 75–80% of reported cases being over 50 years and around 60–70% of them males [3]. Despite the less reported human-to-human transmission, in a world opening up with the resumption of global travel and gatherings, Legionella-contaminated aerosols can be generated in the moist environment of commercial heating, ventilation and air conditioning (HVAC) systems used extensively [4].

The recent clustering of 11 cases at Tucuman, Argentina reported by The Pan American Health Organization (PAHO) and the ministry of health, Argentina makes the discussion about legionella, its transmission, and prevention imperative. Although the exact information for the outbreak is still being looked into, the L. pneumophila, being the most common species to be associated with outbreaks seems to be the culprit with the possible transmission source being inhalation of contaminated aerosols [5].

With the recent pandemic of Coronavirus disease 2019 (COVID-19), the literature has grown to underline the expanded role of ‘ferritin’ in iron metabolism. It is a positive acute phase reactant that gets elevated in many infections including the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It is well known that iron acquisition is essential for the growth of and survival of legionella bacteria [2]. The hyperferritinemia seen during SARS-CoV-2 infection and in the post-COVID phase can form a conducive environment for several iron-dependent pathogenic organisms like mucormycosis [6], and legionella, especially with the threat of newer and re-emerging variants.

The diagnosis of the disease depends on clinical suspicion and lab tests including culture, urine antigen tests, polymerase chain reaction (PCR), direct fluorescent antibody (DFA), and serology (Table 1) [7]. The mild cases without pneumonia usually recover without a pharmacological intervention whereas the moderate to severe Legionnaires' disease requires prompt treatment focused on antibiotic therapy. The most potent agents are fluoroquinolones (levofloxacin>moxifloxacin) and macrolides [8]. But, with the propensity to produce outbreaks, the role of preventive and public health strategies cannot be overstated.